At the end of November 2023, the last patients will be recruited to the EMT2 trial. Two years after that, we will then be able to analyse the results and report whether EPA treatment has beneficial effects for patients after bowel cancer liver metastasis surgery. We expect to share the results with everyone in mid-2026. The trial team will post the results on the website and ensure that hospital teams have a summary of results to share with all participants and their families, on request.
In the meantime, a huge ‘thank you’ to all patients and research staff at the thirteen participating hospitals in England and Wales for making this trial possible. Trials like EMT2 are the only way to know for sure whether a treatment works and the Leeds team appreciate the commitment shown by all, especially in times of uncertainty during the COVID-19 pandemic.
We recently introduced a slight change to the way the trial works so that now we ask patients, who have got to the end of the maximum treatment period (four years), whether we can continue to look at hospital records after trial treatment is stopped until the end of the trial in November 2025. This will help ensure that we have the biggest chance possible to obtain a definitive result from the trial.
Thank you once again to everyone who has participated in and supported EMT2 – the trial team are most grateful.